110 results
Prognostic implications of residual tricuspid regurgitation grading after transcatheter tricuspid valve repair
18 Jun 2024
The take-home message for clinicians is that in the treatment of tricuspid regurgitation, the most frequent valvular disease alongside aortic stenosis, redefining procedural success as a function of the residual degree of TR is crucial.
Reviewer
Reviewer
REC-CAGEFREE II, NOTION-2, LANDMARK: Three major late-breaking trials presented at EuroPCR 2024
15 May 2024
The Course Directors have selected 3 major Late Breaking Trials (LBTs) that were presented for the first time during the 2024 edition of EuroPCR. These trials were selected on account of their design, outcomes and potential to influence daily clinical practice.
NSTEMI in patients in post CABG: a challenging combination
15 May 2024 – From EuroPCR 2024
This session focuses on the management of non-ST-elevation myocardial infarction (NSTEMI) in patients who have previously undergone coronary artery bypass grafting (CABG). Attendees will explore various case presentations and discussions on the challenges and treatment strategies for this complex clinical scenario, including the use of intravascular...
Learning from the Masters - Key learnings from 20 years of transcatheter edge-to-edge repair
15 May 2024 – From EuroPCR 2024
Maurizio Taramasso interviews Ottavio Alfieri, a pioneering figure in valve surgery and a key contributor to the development of transcatheter edge-to-edge repair, honored with the Ethica Award at the 2024 edition of #europcr. Ottavio Alfieri discusses his journey to becoming a cardiac surgeon, the genesis of...
Percutaneous coronary intervention versus coronary artery bypass grafting in patients with left main disease with and without diabetes: findings from a pooled analysis of 4 randomized clinical trials
30 Apr 2024
This analysis shows that diabetic patients undergoing revascularization face substantially higher 5-year rates of all-cause mortality, myocardial infarction, repeat revascularizations, and stroke compared to non-diabetic patients.
Reviewer
Reviewer
TAVI versus SAVR in patients at low to intermediate risk: One year outcomes of the randomized DEDICATE-DZHK6 Trial
08 Apr 2024
Luigi Biasco interviews Moritz Seiffert about the one-year outcomes of the randomized DEDICATE-DZHK6 trial which he presented at ACC.24 in Atlanta.
TAVR was found non-inferior to SAVR in low-risk patients, showing decreased rates of death or stroke at one year. The trial supports TAVR's safety and efficacy, highlighting...
Author
Author
Contemporary surgical & transcatheter treatment options for severe aortic regurgitation patients
05 Dec 2023 – From PCR London Valves 2023
Two cardiac surgeons, Hendrik Treede and Michael Reardon, and an echo specialist, Joao Cavalcante, have been invited to share their views on aortic regurgitation management.
So far, surgery remains the gold standard, and they explain why, by also comparing repair and replacement, before discussing the challenge that...
What is the optimal aortic valve choice in the younger patient: transcatheter or surgery?
29 Nov 2023 – From PCR London Valves 2023
Follow the discussion between Darren Mylotte, Kentaro Hayashida and Ole De Backer to better understand the concept of "young patients" and what it exactly implies, and analyze how best to bring these specific patients to the end of their still potentially long life, by choosing the...
Key questions in tricuspid valve intervention - What can cardiologists learn from surgeons when choosing to repair or replace the tricuspid valve?
19 Nov 2023 – From PCR London Valves 2023
Watch this session to explore the latest approaches in surgical and transcatheter tricuspid valve repair and replacement. Gain insights into the influence of right ventricular dysfunction and pulmonary hypertension on post-procedural outcomes, and understand the bleeding risks linked to oral anticoagulation in patients with tricuspid valve...
The mortality burden of untreated aortic stenosis
14 Nov 2023
This study, based on extensive real-world data, aimed to assess mortality rates across different untreated AS severities and AS treatment rates.
Reviewer
Reviewer
